FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250607210> ?p ?o ?g. }

• W4250607210 endingPage "329" @default.
• W4250607210 startingPage "329" @default.
• W4250607210 abstract "Abstract Background: The HER2 tyrosine kinase inhibitor (TKI) neratinib has exhibited clinical activity in patients with metastatic HER2-mutant cancers. However, responses are heterogeneous across tumor types and not generally prolonged, suggesting mechanisms of de novo and acquired drug resistance. Methods: Neratinib-resistant 5637 (HER2S310F) bladder cancer and OVCAR8 (HER2G776V) ovarian cancer cells were developed after gradual dose escalation. Candidate pathways associated with drug resistance identified by RNA sequencing were validated in a panel of HER2-mutant cell lines and in the SUMMIT basket trial in patients with HER2-mutant cancers. Results: Neratinib-resistant 5637 and OVCAR8 cells were cross-resistant to the HER2 TKIs afatinib and lapatinib. Immunoblot analysis showed that neratinib was still able to suppress HER2, EGFR and HER3 phosphorylation. Gene Set Enrichment and Connectivity Map analyses of RNA-seq data suggested mTORC1 signaling as a druggable pathway driving neratinib resistance. Immunoblot analysis of drug-resistant cells revealed a striking increase in S6K and S6 phosphorylation compared to parental cells. P-S6 levels and viability of drug resistant cells/tumors were ablated upon combining neratinib with the TORC1i everolimus both in vitro and in vivo. Similar results were obtained in cells transfected with Raptor or Rheb siRNAs. Further, neratinib resistance was induced by TSC2 knockdown and resultant TORC1 hyperactivation in parental 5637, OVCAR8, and MCF7 cells expressing L755S or V777L HER2 mutations. RNA-seq also revealed significant enrichment of RAS pathway in neratinib resistant cells which was confirmed by RAS-GTP pulldown. Pharmacological inhibition of RAS signaling using the PI3Ki buparlisib and the MEKi trametinib, or genetic suppression using H-, K-, and N-RAS isoform-specific siRNAs, ablated P-S6 and viability of neratinib resistant cells, suggesting RAS is causally associated with TORC1 hyperactivity and drug resistance. Further, intrinsically neratinib-resistant HER2-mutant cell lines with KRAS or PIK3CA co-mutations [DV90 (ERBB2V842I, KRASG13D), SNUC2A (ERBB2R678Q, KRASG12D, TSC2P1521T), MCF7 (HER2L755S/V777L, PIK3CAH1047R)] were sensitized to neratinib upon the addition of everolimus. Finally, DNA sequencing of tumors (MSK-IMPACT panel; 410 genes) from 141 patients enrolled in the SUMMIT trial showed enrichment of somatic alterations associated with aberrant activation of TORC1 pathway (KRAS, NRAS, NF1, PIK3CA, PIK3R1, AKT1/2, PTEN) in patients exhibiting primary resistance to neratinib. Conclusions: These data suggest that hyperactivation of TORC1 pathway promotes de novo and acquired resistance to neratinib across histologically distinct HER2-mutant cancers. Thus, we propose the combination of neratinib with TORC1 inhibitors is worthy of investigation in patients with HER2-mutant cancers. Citation Format: Dhivya R. Sudhan, Angel Guerrero-Zotano, Helen Won, Paula Gonzales Ericsson, Qi Liu, Teresa Dugger, James Koch, Alison Schram, Alberto Servetto, Richard Cutler, Alshad Lalani, Richard Bryce, Alan Auerbach, Ariella Hanker, Carlos L. Arteaga. Hyperactivation of mTORC1 drives acquired resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 329." @default.
• W4250607210 created "2022-05-12" @default.
• W4250607210 creator A5000701312 @default.
• W4250607210 creator A5007997858 @default.
• W4250607210 creator A5018638765 @default.
• W4250607210 creator A5020373259 @default.
• W4250607210 creator A5030674323 @default.
• W4250607210 creator A5042749420 @default.
• W4250607210 creator A5043393829 @default.
• W4250607210 creator A5043946489 @default.
• W4250607210 creator A5045194333 @default.
• W4250607210 creator A5062479121 @default.
• W4250607210 creator A5066832083 @default.
• W4250607210 creator A5075517542 @default.
• W4250607210 creator A5085028455 @default.
• W4250607210 creator A5085464902 @default.
• W4250607210 creator A5088495181 @default.
• W4250607210 date "2019-07-01" @default.
• W4250607210 modified "2023-09-27" @default.
• W4250607210 title "Abstract 329: Hyperactivation of mTORC1 drives acquired resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers" @default.
• W4250607210 doi "https://doi.org/10.1158/1538-7445.am2019-329" @default.
• W4250607210 hasPublicationYear "2019" @default.
• W4250607210 type Work @default.
• W4250607210 citedByCount "0" @default.
• W4250607210 crossrefType "journal-article" @default.
• W4250607210 hasAuthorship W4250607210A5000701312 @default.
• W4250607210 hasAuthorship W4250607210A5007997858 @default.
• W4250607210 hasAuthorship W4250607210A5018638765 @default.
• W4250607210 hasAuthorship W4250607210A5020373259 @default.
• W4250607210 hasAuthorship W4250607210A5030674323 @default.
• W4250607210 hasAuthorship W4250607210A5042749420 @default.
• W4250607210 hasAuthorship W4250607210A5043393829 @default.
• W4250607210 hasAuthorship W4250607210A5043946489 @default.
• W4250607210 hasAuthorship W4250607210A5045194333 @default.
• W4250607210 hasAuthorship W4250607210A5062479121 @default.
• W4250607210 hasAuthorship W4250607210A5066832083 @default.
• W4250607210 hasAuthorship W4250607210A5075517542 @default.
• W4250607210 hasAuthorship W4250607210A5085028455 @default.
• W4250607210 hasAuthorship W4250607210A5085464902 @default.
• W4250607210 hasAuthorship W4250607210A5088495181 @default.
• W4250607210 hasConcept C121608353 @default.
• W4250607210 hasConcept C2777329042 @default.
• W4250607210 hasConcept C2779413316 @default.
• W4250607210 hasConcept C2779438470 @default.
• W4250607210 hasConcept C2779786085 @default.
• W4250607210 hasConcept C2780580887 @default.
• W4250607210 hasConcept C2780586478 @default.
• W4250607210 hasConcept C502942594 @default.
• W4250607210 hasConcept C530470458 @default.
• W4250607210 hasConcept C54355233 @default.
• W4250607210 hasConcept C62478195 @default.
• W4250607210 hasConcept C86554907 @default.
• W4250607210 hasConcept C86803240 @default.
• W4250607210 hasConcept C95444343 @default.
• W4250607210 hasConcept C98490376 @default.
• W4250607210 hasConceptScore W4250607210C121608353 @default.
• W4250607210 hasConceptScore W4250607210C2777329042 @default.
• W4250607210 hasConceptScore W4250607210C2779413316 @default.
• W4250607210 hasConceptScore W4250607210C2779438470 @default.
• W4250607210 hasConceptScore W4250607210C2779786085 @default.
• W4250607210 hasConceptScore W4250607210C2780580887 @default.
• W4250607210 hasConceptScore W4250607210C2780586478 @default.
• W4250607210 hasConceptScore W4250607210C502942594 @default.
• W4250607210 hasConceptScore W4250607210C530470458 @default.
• W4250607210 hasConceptScore W4250607210C54355233 @default.
• W4250607210 hasConceptScore W4250607210C62478195 @default.
• W4250607210 hasConceptScore W4250607210C86554907 @default.
• W4250607210 hasConceptScore W4250607210C86803240 @default.
• W4250607210 hasConceptScore W4250607210C95444343 @default.
• W4250607210 hasConceptScore W4250607210C98490376 @default.
• W4250607210 hasIssue "13_Supplement" @default.
• W4250607210 hasLocation W42506072101 @default.
• W4250607210 hasOpenAccess W4250607210 @default.
• W4250607210 hasPrimaryLocation W42506072101 @default.
• W4250607210 hasRelatedWork W1844416723 @default.
• W4250607210 hasRelatedWork W2107729471 @default.
• W4250607210 hasRelatedWork W2139154837 @default.
• W4250607210 hasRelatedWork W2492858695 @default.
• W4250607210 hasRelatedWork W2529854314 @default.
• W4250607210 hasRelatedWork W2566661518 @default.
• W4250607210 hasRelatedWork W2604573213 @default.
• W4250607210 hasRelatedWork W2898399140 @default.
• W4250607210 hasRelatedWork W4322771471 @default.
• W4250607210 hasRelatedWork W4362540774 @default.
• W4250607210 hasVolume "79" @default.
• W4250607210 isParatext "false" @default.
• W4250607210 isRetracted "false" @default.
• W4250607210 workType "article" @default.